A breast tumor is considered HER2 + only if it has an immunohistochemistry score (IHC) 3+ or IHC 2+ /in situ hybridization positive (ISH)+, and a diagnosis of HER2 + indicates that a patient could benefit from one year of trastuzumab therapy [3]. The gene discussed is ERBB2; the disease is breast neoplasm.